Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keeping Track: A Long-Awaited Approval For Generic EpiPen, Cancer Product Labels Expand And Constrict

Executive Summary

The latest drug development news and highlights from our US FDA Performance Tracker. 
Advertisement

Related Content

Aimmune Accelerates Commercial Planning For Peanut Allergy Drug
US FDA Releases Slew Of Guidances On A Fell Day For Complex Generics
Keeping Track: Zelboraf Takes Breakthrough Path For Rare Blood Disease; Teva Resubmits Generic EpiPen
Complex Products At US FDA: Adamis' Epi-Pen Alternative OKed; Sandoz Advair ANDA Accepted
Generic Industry Wants More Guidance On Demonstrating Equivalence Of Drug-Device Combinations
EpiPen Price Hearing: House Plays Bootleg Tape Of Shkreli Event
EpiPen Familiarity May Prove Tough Hurdle For Generics
Mylan’s EpiPen Exclusivity Saved Again As Teva Reports CRL
Keeping Track: Dueling 'Breakthroughs' For Peanut Allergy
'Breakthrough' status granted to Aimmune's peanut allergy drug

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS123720

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel